Table 4. TAS2R38 variants and diplotypes and the association with gastric cancer risk.

	Model 1 OR (95% CI)*	P	Model 2 OR (95% CI)†	P
A49P
PP	1.000 (reference)		1.000 (reference)
PA	1.392 (1.089–1.780)	0.005	1.515 (1.149–1.996)	0.001
AA	1.025 (0.733–1.435)	0.361	0.983 (0.676–1.429)	0.190
V262A
AA	1.000 (reference)		1.000 (reference)
AV	1.404 (1.098–1.794)	0.003	1.525 (1.157–2.009)	0.001
VV	0.995 (0.709–1.396)	0.261	0.957 (0.656–1.395)	0.140
I296V
VV	1.000 (reference)		1.000 (reference)
VI	1.404 (1.098–1.794)	0.003	1.525 (1.157–2.009)	0.001
II	0.995 (0.709–1.396)	0.261	0.957 (0.656–1.395)	0.140
Diplotype
PAV/PAV	1.000 (reference)		1.000 (reference)‡
PAV/AVI	1.392 (1.089–1.780)	0.004	1.513 (1.148–1.994)	0.001
AVI/AVI	0.995 (0.709–1.396)	0.272	0.956 (0.656–1.394)	0.145

Subjects with AVI/AAV diplotype were excluded from the analyses because of limited numbers (n = 2).

^*Model 1: crude OR and 95% CI.

^†Model 2: ORs computed after adjusting for sex, age, body mass index, smoking and drinking status, regular exercise and Helicobacter pylori infection (please refer to Supplementary Table S2 for the effect of potential confounders). OR = odds ratio; CI = confidence interval.